Society on Sarcopenia, Cachexia and Wasting Disorders: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Yanncol (talk | contribs)
49 edits
No edit summary
Citation bot (talk | contribs)
Bots
4,950,072 edits
m Alter: template type, volume, pages, journal, title, url, isbn. Add: issue, doi, doi-broken-date, pmid. Removed parameters. You can use this bot yourself. Report bugs here. | Headbomb
Line 6: Line 6:
The '''Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)''' is an international and multidisciplinary non-profit organization.<ref>{{Cite news|url=https://www.gagivesday.org/c/GGD/a/cachexia|title=Come Together to support a cause that matters to you!|access-date=2016-12-07}}</ref> It focuses on [[Cachexia]]<ref>[http://www.cancercachexia.com/what-is-cancer-cachexia What is cancer cachexia]</ref> and [[Sarcopenia]].
The '''Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)''' is an international and multidisciplinary non-profit organization.<ref>{{Cite news|url=https://www.gagivesday.org/c/GGD/a/cachexia|title=Come Together to support a cause that matters to you!|access-date=2016-12-07}}</ref> It focuses on [[Cachexia]]<ref>[http://www.cancercachexia.com/what-is-cancer-cachexia What is cancer cachexia]</ref> and [[Sarcopenia]].


Cachexia and sarcopenia are a major public health problem: frequent, costly, and deadly.<ref>{{Cite journal|last=Farkas|first=Jerneja|last2=von Haehling|first2=Stephan|last3=Kalantar-Zadeh|first3=Kamyar|last4=Morley|first4=John E.|last5=Anker|first5=Stefan D.|last6=Lainscak|first6=Mitja|date=2016-12-07|title=Cachexia as a major public health problem: frequent, costly, and deadly|journal=Journal of Cachexia, Sarcopenia and Muscle|volume=4|issue=3|pages=173–178|doi=10.1007/s13539-013-0105-y|issn=2190-5991|pmc=3774921|pmid=23539127}}</ref> . They are often under-diagnosed and patients groups try to improve awareness about them<ref>{{Cite news|url=http://www.baltimoresun.com/health/bs-hs-sarcopenia-muscle-loss-20180119-story.html|title=Groups seek better diagnosis and treatment of debilitating muscle loss in seniors|last=McDaniels|first=Andrea K.|work=baltimoresun.com|access-date=2018-02-09|language=en-US}}</ref>. Cachexia has been coined as the "last illness".<ref>{{Cite journal|last=Lok|first=Corie|date=2015-12-10|title=Cachexia: The last illness|url=http://www.nature.com/news/cachexia-the-last-illness-1.18961|journal=Nature|volume=528|issue=7581|pages=182–183|doi=10.1038/528182a}}</ref> The prevalence of cachexia ranges from 5–15% in end-stage chronic heart failure to 50–80% in advanced malignant cancer.<ref>[https://www.youtube.com/watch?v=i6tq4hKkqJc]</ref> It is estimated that 5 Million Americans have the condition and Cachexia is frequently occurring in patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD), HIV, Multiple sclerosis, neurological diseases, and rheumatoid arthritis.<ref>{{Cite news|url=http://www.medicalnewstoday.com/articles/315312.php|title=Cachexia: Symptoms, Treatment, and Outlook|newspaper=Medical News Today|language=en|access-date=2017-01-24}}</ref> Mortality rates of patients with cachexia range from 15–25% per year in severe COPD through 20–40% per year in patients with chronic heart failure or chronic kidney disease to 20–80% in cancer cachexia.<ref>{{Cite journal|last=von Haehling|first=Stephan|last2=Anker|first2=Markus S.|last3=Anker|first3=Stefan D.|date=2016-12-01|title=Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016|url=http://onlinelibrary.wiley.com/doi/10.1002/jcsm.12167/abstract|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=7|issue=5|pages=507–509|doi=10.1002/jcsm.12167|issn=2190-6009|pmc=5114624|pmid=27891294}}</ref> SCWD was founded in 2008 on the initiative of Prof. Stefan D. Anker,<ref>{{Cite web|title=Curriculum vitae|url=http://www.ema.europa.eu/docs/en_GB/document_library/contacts/ankers_CV.pdf}}</ref> Germany and Dr. John E. Morley,<ref>{{Cite web|website=Saint Louis University|title=One of the nation' foremost authorities on geriatrics|url=http://www.slu.edu/bio-morley}}</ref> USA. It is made up of an international and multidisciplinary group of healthcare professionals in the fields of sarcopenia, cachexia and muscle wasting.<ref>{{Cite journal|journal=Newswire|title=The Society On Sarcopenia, Cachexia & Wasting Disorders Announces Its 1st Cancer Cachexia Conference In Boston, USA|url=https://www.newswire.com/the-society-on-sarcopenia-cachexia/172418}}</ref>
Cachexia and sarcopenia are a major public health problem: frequent, costly, and deadly.<ref>{{Cite journal|last=Farkas|first=Jerneja|last2=von Haehling|first2=Stephan|last3=Kalantar-Zadeh|first3=Kamyar|last4=Morley|first4=John E.|last5=Anker|first5=Stefan D.|last6=Lainscak|first6=Mitja|date=2016-12-07|title=Cachexia as a major public health problem: frequent, costly, and deadly|journal=Journal of Cachexia, Sarcopenia and Muscle|volume=4|issue=3|pages=173–178|doi=10.1007/s13539-013-0105-y|issn=2190-5991|pmc=3774921|pmid=23539127}}</ref> . They are often under-diagnosed and patients groups try to improve awareness about them<ref>{{Cite news|url=http://www.baltimoresun.com/health/bs-hs-sarcopenia-muscle-loss-20180119-story.html|title=Groups seek better diagnosis and treatment of debilitating muscle loss in seniors|last=McDaniels|first=Andrea K.|work=baltimoresun.com|access-date=2018-02-09|language=en-US}}</ref>. Cachexia has been coined as the "last illness".<ref>{{Cite journal|last=Lok|first=Corie|date=2015-12-10|title=Cachexia: The last illness|url=http://www.nature.com/news/cachexia-the-last-illness-1.18961|journal=Nature|volume=528|issue=7581|pages=182–183|doi=10.1038/528182a|pmid=26659165}}</ref> The prevalence of cachexia ranges from 5–15% in end-stage chronic heart failure to 50–80% in advanced malignant cancer.<ref>[https://www.youtube.com/watch?v=i6tq4hKkqJc]</ref> It is estimated that 5 Million Americans have the condition and Cachexia is frequently occurring in patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD), HIV, Multiple sclerosis, neurological diseases, and rheumatoid arthritis.<ref>{{Cite news|url=http://www.medicalnewstoday.com/articles/315312.php|title=Cachexia: Symptoms, Treatment, and Outlook|newspaper=Medical News Today|language=en|access-date=2017-01-24}}</ref> Mortality rates of patients with cachexia range from 15–25% per year in severe COPD through 20–40% per year in patients with chronic heart failure or chronic kidney disease to 20–80% in cancer cachexia.<ref>{{Cite journal|last=von Haehling|first=Stephan|last2=Anker|first2=Markus S.|last3=Anker|first3=Stefan D.|date=2016-12-01|title=Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=7|issue=5|pages=507–509|doi=10.1002/jcsm.12167|issn=2190-6009|pmc=5114624|pmid=27891294}}</ref> SCWD was founded in 2008 on the initiative of Prof. Stefan D. Anker,<ref>{{Cite web|title=Curriculum vitae|url=http://www.ema.europa.eu/docs/en_GB/document_library/contacts/ankers_CV.pdf}}</ref> Germany and Dr. John E. Morley,<ref>{{Cite web|website=Saint Louis University|title=One of the nation' foremost authorities on geriatrics|url=http://www.slu.edu/bio-morley}}</ref> USA. It is made up of an international and multidisciplinary group of healthcare professionals in the fields of sarcopenia, cachexia and muscle wasting.<ref>{{Cite journal|journal=Newswire|title=The Society On Sarcopenia, Cachexia & Wasting Disorders Announces Its 1st Cancer Cachexia Conference In Boston, USA|url=https://www.newswire.com/the-society-on-sarcopenia-cachexia/172418}}</ref>


The purpose and objectives of the Society on Sarcopenia, Cachexia and Wasting Disorders ('''SCWD''') are to:
The purpose and objectives of the Society on Sarcopenia, Cachexia and Wasting Disorders ('''SCWD''') are to:
* To improve the understanding, diagnosis and treatment of skeletal muscle wasting in various disease conditions and aging<ref>{{Cite web|url=http://research.longfonds.nl/database/society-on-sarcopenia-cachexia-and-wasting-disorders|title=Society on sarcopenia, cachexia and wasting disorders|website=research.longfonds.nl|access-date=2016-12-07}}</ref>
* To improve the understanding, diagnosis and treatment of skeletal muscle wasting in various disease conditions and aging<ref>{{Cite web|url=http://research.longfonds.nl/database/society-on-sarcopenia-cachexia-and-wasting-disorders|title=Society on sarcopenia, cachexia and wasting disorders|website=research.longfonds.nl|access-date=2016-12-07}}</ref>
* Educate healthcare professionals
* Educate healthcare professionals
* Form partnerships with other professional societies<ref>{{Cite web|title=Journal of Cachexia, Sarcopenia and Muscle - Society Information - | publisher = Wiley Online Library|url=http://onlinelibrary.wiley.com/journal/10.1007/13539.2190-6009/homepage/Society.html }}</ref>
* Form partnerships with other professional societies<ref>{{Cite journal|title=Journal of Cachexia, Sarcopenia and Muscle - Society Information - | publisher = Wiley Online Library|url=http://onlinelibrary.wiley.com/journal/10.1007/13539.2190-6009/homepage/Society.html | doi-broken-date = 2018-08-30| doi = 10.1007/13539.2190-6009/homepage/Society}}</ref>


== Legal Structure and Board ==
== Legal Structure and Board ==
The Society on Sarcopenia, Cachexia and Wasting Disorders is a non-profit scientific organization (501 c3)<ref>[http://990s.foundationcenter.org/990_pdf_archive/800/800419218/800419218_201212_990.pdf]</ref> registered in the United States of America and Switzerland. The president is Prof. Stefan Anker, Germany who is also vice-president of the European Society of Cardiology,<ref>{{Cite web|url=http://www.escardio.org/The-ESC/Governance/ESC-Board|title=ESC Board|website=www.escardio.org|access-date=2016-12-07}}</ref> the Vice-president is Dr. John Morley, USA and the treasurer is Prof. Andrew J. Coats, United Kingdom who particularly investigated cardiac cachexia at an early stage.<ref>{{Cite journal|last=Coats|first=Andrew JS|year=2002|title=Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath|url=http://www.internationaljournalofcardiology.com/article/S0167-5273(02)00242-5/fulltext|journal=International Journal of Cardiology|volume=|pages=|doi=10.1016/s0167-5273(02)00242-5}}</ref><br />The Board is made up of : <br />[[Stefan D. Anker]] (President<ref>{{Cite news|url=https://www.prevention.com/health/wasting-syndrome|title=This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know|date=2017-09-27|work=Prevention|access-date=2018-02-09|language=en}}</ref>) – Berlin, Germany <br />Josep M. Argiles – Barcelona, Spain <br />Vickie E. Baracos – Edmonton, Canada <br />[[Andrew Justin Stewart Coats|Andrew J. S. Coats]] (Treasurer) – Norwich, UK<br />Wolfram Doehner – Berlin, Germany <br />William J. Evans<ref>[http://aginginmotion.org/regulatory-recognition-key-to-moving-forward-on-sarcopenia-interview-with-dr-bill-evans]</ref> – Duke University, USA <br /> Luigi Ferrucci<ref>[https://www.nia.nih.gov/newsroom/announcements/2011/05/luigi-ferrucci-named-nia-scientific-director]</ref> – Baltimore, USA<br /> David J. Glass – Boston, USA<br />Akio Inui – Kobe, Japan<br />Aminah Jatoi – Rochester, USA<br />[[Kamyar Kalantar-Zadeh]] – Los Angeles, USA<br />John E. Morley (Vice-president) – St. Louis, USA<br />Filippo Rossi-Fanelli – Rome, Italy<br />Florian Strasser – St. Gallen, Switzerland <br />Stephan von Haehling – Göttingen, Germany
The Society on Sarcopenia, Cachexia and Wasting Disorders is a non-profit scientific organization (501 c3)<ref>[http://990s.foundationcenter.org/990_pdf_archive/800/800419218/800419218_201212_990.pdf]</ref> registered in the United States of America and Switzerland. The president is Prof. Stefan Anker, Germany who is also vice-president of the European Society of Cardiology,<ref>{{Cite web|url=http://www.escardio.org/The-ESC/Governance/ESC-Board|title=ESC Board|website=www.escardio.org|access-date=2016-12-07}}</ref> the Vice-president is Dr. John Morley, USA and the treasurer is Prof. Andrew J. Coats, United Kingdom who particularly investigated cardiac cachexia at an early stage.<ref>{{Cite journal|last=Coats|first=Andrew JS|year=2002|title=Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath|url=http://www.internationaljournalofcardiology.com/article/S0167-5273(02)00242-5/fulltext|journal=International Journal of Cardiology|volume=85|pages=133-139|doi=10.1016/s0167-5273(02)00242-5}}</ref><br />The Board is made up of : <br />[[Stefan D. Anker]] (President<ref>{{Cite news|url=https://www.prevention.com/health/wasting-syndrome|title=This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know|date=2017-09-27|work=Prevention|access-date=2018-02-09|language=en}}</ref>) – Berlin, Germany <br />Josep M. Argiles – Barcelona, Spain <br />Vickie E. Baracos – Edmonton, Canada <br />[[Andrew Justin Stewart Coats|Andrew J. S. Coats]] (Treasurer) – Norwich, UK<br />Wolfram Doehner – Berlin, Germany <br />William J. Evans<ref>[http://aginginmotion.org/regulatory-recognition-key-to-moving-forward-on-sarcopenia-interview-with-dr-bill-evans]</ref> – Duke University, USA <br /> Luigi Ferrucci<ref>[https://www.nia.nih.gov/newsroom/announcements/2011/05/luigi-ferrucci-named-nia-scientific-director]</ref> – Baltimore, USA<br /> David J. Glass – Boston, USA<br />Akio Inui – Kobe, Japan<br />Aminah Jatoi – Rochester, USA<br />[[Kamyar Kalantar-Zadeh]] – Los Angeles, USA<br />John E. Morley (Vice-president) – St. Louis, USA<br />Filippo Rossi-Fanelli – Rome, Italy<br />Florian Strasser – St. Gallen, Switzerland <br />Stephan von Haehling – Göttingen, Germany


Prof Ken Fearon was a Board member until he passed away in September 2016.<ref>{{Cite journal|last=|first=|year=|title=editorial|url=http://www.clinicalnutritionjournal.com/article/S0261-5614(16)31280-8/pdf|journal=Clinical nutrition|volume=|pages=|via=}}</ref> He had received the Hippocrates Award from the Society.<ref>{{Cite web|url=http://www.heraldscotland.com/opinion/obituaries/14746676.Obituary___Kenneth_Fearon__professor_of_surgical_oncology/|title=Obituary - Kenneth Fearon, professor of surgical oncology|website=HeraldScotland|access-date=2016-12-07}}</ref> Professor Fearon was particularly involved in cancer cachexia: leading an international consensus.<ref>{{Cite journal|last=Fearon|first=Kenneth|last2=Strasser|first2=Florian|last3=Anker|first3=Stefan D.|last4=Bosaeus|first4=Ingvar|last5=Bruera|first5=Eduardo|last6=Fainsinger|first6=Robin L.|last7=Jatoi|first7=Aminah|last8=Loprinzi|first8=Charles|last9=MacDonald|first9=Neil|date=2011-05-01|title=Definition and classification of cancer cachexia: an international consensus|journal=The Lancet. Oncology|volume=12|issue=5|pages=489–495|doi=10.1016/S1470-2045(10)70218-7|issn=1474-5488|pmid=21296615}}</ref>
Prof Ken Fearon was a Board member until he passed away in September 2016.<ref>{{Cite journal|last=|first=|year=|title=editorial|url=http://www.clinicalnutritionjournal.com/article/S0261-5614(16)31280-8/pdf|journal=Clinical Nutrition|volume=|pages=|via=}}</ref> He had received the Hippocrates Award from the Society.<ref>{{Cite web|url=http://www.heraldscotland.com/opinion/obituaries/14746676.Obituary___Kenneth_Fearon__professor_of_surgical_oncology/|title=Obituary - Kenneth Fearon, professor of surgical oncology|website=HeraldScotland|access-date=2016-12-07}}</ref> Professor Fearon was particularly involved in cancer cachexia: leading an international consensus.<ref>{{Cite journal|last=Fearon|first=Kenneth|last2=Strasser|first2=Florian|last3=Anker|first3=Stefan D.|last4=Bosaeus|first4=Ingvar|last5=Bruera|first5=Eduardo|last6=Fainsinger|first6=Robin L.|last7=Jatoi|first7=Aminah|last8=Loprinzi|first8=Charles|last9=MacDonald|first9=Neil|date=2011-05-01|title=Definition and classification of cancer cachexia: an international consensus|journal=The Lancet. Oncology|volume=12|issue=5|pages=489–495|doi=10.1016/S1470-2045(10)70218-7|issn=1474-5488|pmid=21296615}}</ref>


== Educational initiatives ==
== Educational initiatives ==


=== Conferences ===
=== Conferences ===
Since 2000<ref>{{Cite journal|last=Anker|first=Markus S.|last2=von Haehling|first2=Stephan|last3=Springer|first3=Jochen|last4=Banach|first4=Maciej|last5=Anker|first5=Stefan D.|date=2013-02-21|title=Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology|journal=Archives of Medical Science : AMS|volume=9|issue=1|pages=166–171|doi=10.5114/aoms.2013.33356|issn=1734-1922|pmc=3598129|pmid=23515589}}</ref> the SCWD Society has organized several international conferences.<ref>{{Cite journal|date=2010-09-01|title=Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5–8, 2009|url=http://onlinelibrary.wiley.com/doi/10.1007/s13539-010-0001-7/abstract|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=1|issue=1|pages=43–128|doi=10.1007/s13539-010-0001-7|issn=2190-6009|pmc=3060650|pmid=22477519}}</ref> In 2009, the conference<ref>{{Cite web|url=http://medschool.slu.edu/uploads/images/5th_Cachexia_Conference_2009.pdf}}</ref> took place in Barcelona, Spain. In 2011, the 7th conference took place in Italy.<ref>{{Cite web|url=http://www.huffingtonpost.com/andrew-dudley/elderly-women-prefer-deat_b_5114875.html}}</ref> One of them took place in Kobe,<ref>{{Cite web|url=http://www.cancercachexia.com/literature-watch/84_congress-report-7th-cachexia-conference-kobeosaka-japan-december}}</ref> Japan. Those conferences have taken place every two years. However, in 2015, in Paris,<ref>[https://www.goedoc.uni-goettingen.de/goescholar/bitstream/handle/1/13727/jcsm12110.pdf?sequence=1]</ref> it was decided to organize the conferences annually.<ref>{{Cite journal|date=2016-02-22|title=The times they are a‐changin’: the Cachexia Conference goes annual|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|pmc=4771211|pmid=27066313|doi=10.1002/jcsm.12110|volume=7|pages=3–4 | last1 = von Haehling | first1 = S | last2 = Anker | first2 = SD}}</ref>
Since 2000<ref>{{Cite journal|last=Anker|first=Markus S.|last2=von Haehling|first2=Stephan|last3=Springer|first3=Jochen|last4=Banach|first4=Maciej|last5=Anker|first5=Stefan D.|date=2013-02-21|title=Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology|journal=Archives of Medical Science : AMS|volume=9|issue=1|pages=166–171|doi=10.5114/aoms.2013.33356|issn=1734-1922|pmc=3598129|pmid=23515589}}</ref> the SCWD Society has organized several international conferences.<ref>{{Cite journal|date=2010-09-01|title=Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5–8, 2009|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=1|issue=1|pages=43–128|doi=10.1007/s13539-010-0001-7|issn=2190-6009|pmc=3060650|pmid=22477519}}</ref> In 2009, the conference<ref>{{Cite web|url=http://medschool.slu.edu/uploads/images/5th_Cachexia_Conference_2009.pdf}}</ref> took place in Barcelona, Spain. In 2011, the 7th conference took place in Italy.<ref>{{Cite web|url=http://www.huffingtonpost.com/andrew-dudley/elderly-women-prefer-deat_b_5114875.html}}</ref> One of them took place in Kobe,<ref>{{Cite web|url=http://www.cancercachexia.com/literature-watch/84_congress-report-7th-cachexia-conference-kobeosaka-japan-december}}</ref> Japan. Those conferences have taken place every two years. However, in 2015, in Paris,<ref>[https://www.goedoc.uni-goettingen.de/goescholar/bitstream/handle/1/13727/jcsm12110.pdf?sequence=1]</ref> it was decided to organize the conferences annually.<ref>{{Cite journal|date=2016-02-22|title=The times they are a‐changin': the Cachexia Conference goes annual|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|pmc=4771211|pmid=27066313|doi=10.1002/jcsm.12110|volume=7|issue=1|pages=3–4 | last1 = von Haehling | first1 = S | last2 = Anker | first2 = SD}}</ref>
The location of the 2016 congress is Berlin on 10–11 December 2016.<ref>{{Cite web|url=http://cancercachexia2016.com/html/events.html|website=cancercachexia2016}}</ref> The programme includes a statistical seminar, a mentor or career session and sessions on cachexia, sarcopenia and muscle wasting.<ref>{{Cite web|url=http://www.sinu.it/public//program-berlin-7-10.pdf}}</ref>
The location of the 2016 congress is Berlin on 10–11 December 2016.<ref>{{Cite web|url=http://cancercachexia2016.com/html/events.html|website=cancercachexia2016}}</ref> The programme includes a statistical seminar, a mentor or career session and sessions on cachexia, sarcopenia and muscle wasting.<ref>{{Cite web|url=http://www.sinu.it/public//program-berlin-7-10.pdf}}</ref>


It addresses frailty, sarcopenia and cachexia resulting from the following diseases or chronic conditions: Cancer, Cardiovascular Disease, Death, Dying & Grief, Dementia/Alzheimer's Disease, Diabetes, Heart Failure and Ageing.<ref>{{Cite journal|last=von Haehling|first=Stephan|last2=Anker|first2=Stefan D.|date=2010-09-01|title=Cachexia as a major underestimated and unmet medical need: facts and numbers|url=http://onlinelibrary.wiley.com/doi/10.1007/s13539-010-0002-6/abstract|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=1|issue=1|pages=1–5|doi=10.1007/s13539-010-0002-6|issn=2190-6009|pmc=3060651|pmid=21475699}}</ref> Update on Anabolics and Related Therapie sare also provided.<ref>{{Cite web|url=http://www.prnewswire.co.uk/news-releases/helsinn-initiates-extension-study-in-late-stage-anamorelin-clinical-program-for-non-small-cell-lung-cancer-associated-anorexiacachexia-144794085.html|title=Helsinn Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung /PR Newswire UK/|last=Group|first=Helsinn|website=www.prnewswire.co.uk|access-date=2016-12-08}}</ref> Results of clinical trials are also presented, such a sdata from a Phase II clinical trial of MT-102 in cancer-related cachexia presented in Kobe in 2013.<ref>{{Cite web|url=http://www.lundbeckfonden.com/page75.aspx?newsid75=258|title=Lundbeckfond Ventures › MID-STAGE CLINICAL STUDY OF WASTING DISEASE THERAPEUTIC MT-102 SHOWS REVERSAL OF CANCER-RELATED WASTING|website=www.lundbeckfonden.com|access-date=2016-12-12}}</ref>
It addresses frailty, sarcopenia and cachexia resulting from the following diseases or chronic conditions: Cancer, Cardiovascular Disease, Death, Dying & Grief, Dementia/Alzheimer's Disease, Diabetes, Heart Failure and Ageing.<ref>{{Cite journal|last=von Haehling|first=Stephan|last2=Anker|first2=Stefan D.|date=2010-09-01|title=Cachexia as a major underestimated and unmet medical need: facts and numbers|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=1|issue=1|pages=1–5|doi=10.1007/s13539-010-0002-6|issn=2190-6009|pmc=3060651|pmid=21475699}}</ref> Update on Anabolics and Related Therapie sare also provided.<ref>{{Cite web|url=http://www.prnewswire.co.uk/news-releases/helsinn-initiates-extension-study-in-late-stage-anamorelin-clinical-program-for-non-small-cell-lung-cancer-associated-anorexiacachexia-144794085.html|title=Helsinn Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung /PR Newswire UK/|last=Group|first=Helsinn|website=www.prnewswire.co.uk|access-date=2016-12-08}}</ref> Results of clinical trials are also presented, such a sdata from a Phase II clinical trial of MT-102 in cancer-related cachexia presented in Kobe in 2013.<ref>{{Cite web|url=http://www.lundbeckfonden.com/page75.aspx?newsid75=258|title=Lundbeckfond Ventures ' MID-STAGE CLINICAL STUDY OF WASTING DISEASE THERAPEUTIC MT-102 SHOWS REVERSAL OF CANCER-RELATED WASTING|website=www.lundbeckfonden.com|access-date=2016-12-12}}</ref>


<br />
<br />
Target audience: Internists, Oncologists, Geriatricians, Cardiologists, Nephrologists, Palliative care specialists, Nurse Practitioners and Primary Care Providers.
Target audience: Internists, Oncologists, Geriatricians, Cardiologists, Nephrologists, Palliative care specialists, Nurse Practitioners and Primary Care Providers.


Attendance:<ref>{{Cite journal|last=Haehling|first=Stephan von|last2=Anker|first2=Stefan D.|date=2011-11-09|title=The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area|url=https://link.springer.com/article/10.1007/s13539-011-0048-0|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=2|issue=4|pages=189–190|doi=10.1007/s13539-011-0048-0|issn=2190-5991|pmc=3222803|pmid=22207906}}</ref>
Attendance:<ref>{{Cite journal|last=Haehling|first=Stephan von|last2=Anker|first2=Stefan D.|date=2011-11-09|title=The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=2|issue=4|pages=189–190|doi=10.1007/s13539-011-0048-0|issn=2190-5991|pmc=3222803|pmid=22207906}}</ref>
{| class="wikitable"
{| class="wikitable"
|-
|-
Line 50: Line 50:
| 2015 || 8th || Paris || 500
| 2015 || 8th || Paris || 500
|}<br />A charity dinner is sometimes organised during SCWD Conférences such as in 2011 in Milan with the participation of [[Lisa Niemi]].<ref>{{Cite web|url=https://www.newswire.com/6th-cachexia-conference-lisa-niemi/134345|title=6th Cachexia Conference: Lisa Niemi-Swayze Slated as Keynote Speaker at SCWD Charity Dinner|website=www.newswire.com|access-date=2016-12-07}}</ref>
|}<br />A charity dinner is sometimes organised during SCWD Conférences such as in 2011 in Milan with the participation of [[Lisa Niemi]].<ref>{{Cite web|url=https://www.newswire.com/6th-cachexia-conference-lisa-niemi/134345|title=6th Cachexia Conference: Lisa Niemi-Swayze Slated as Keynote Speaker at SCWD Charity Dinner|website=www.newswire.com|access-date=2016-12-07}}</ref>
Posters: each meeting features 120-200 posters.<ref>{{Cite journal|date=2012-01-31|title=Abstracts of the 6th Cachexia Conference, Milan, Italy, December 8–10, 2011 (Part 2)|url=https://link.springer.com/article/10.1007/s13539-012-0056-8|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=3|issue=1|pages=51–68|doi=10.1007/s13539-012-0056-8|issn=2190-5991|pmc=3302985|pmid=22460563}}</ref>
Posters: each meeting features 120-200 posters.<ref>{{Cite journal|date=2012-01-31|title=Abstracts of the 6th Cachexia Conference, Milan, Italy, December 8–10, 2011 (Part 2)|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=3|issue=1|pages=51–68|doi=10.1007/s13539-012-0056-8|issn=2190-5991|pmc=3302985|pmid=22460563}}</ref>


The SCWD releases regular highlights of its meetings.<ref>{{Cite journal|last=Ebner|first=Nicole|last2=Werner|first2=Claudia G.|last3=Doehner|first3=Wolfram|last4=Anker|first4=Stefan D.|last5=Haehling|first5=Stephan von|date=2012-03-02|title=Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference|url=https://link.springer.com/article/10.1007/s13539-012-0061-y|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=3|issue=1|pages=45–50|doi=10.1007/s13539-012-0061-y|issn=2190-5991|pmc=3302986|pmid=22460618}}</ref>
The SCWD releases regular highlights of its meetings.<ref>{{Cite journal|last=Ebner|first=Nicole|last2=Werner|first2=Claudia G.|last3=Doehner|first3=Wolfram|last4=Anker|first4=Stefan D.|last5=Haehling|first5=Stephan von|date=2012-03-02|title=Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=3|issue=1|pages=45–50|doi=10.1007/s13539-012-0061-y|issn=2190-5991|pmc=3302986|pmid=22460618}}</ref>


=== Consensus meetings ===
=== Consensus meetings ===
Since 2006, the SCWD has also organized several consensus meetings to address issues related to the definition of cachexia, sarcopenia<ref>{{Cite journal|last=Morley|first=John E.|last2=Abbatecola|first2=Angela Marie|last3=Argiles|first3=Josep M.|last4=Baracos|first4=Vickie|last5=Bauer|first5=Juergen|last6=Bhasin|first6=Shalender|last7=Cederholm|first7=Tommy|last8=Coats|first8=Andrew J. Stewart|last9=Cummings|first9=Steven R.|date=2011-07-01|title=Sarcopenia with limited mobility: an international consensus|journal=Journal of the American Medical Directors Association|volume=12|issue=6|pages=403–409|doi=10.1016/j.jamda.2011.04.014|issn=1538-9375|pmc=5100674|pmid=21640657}}</ref> as well the regulatory pathways for treatment development in cachexia, sarcopenia and the syndrome of muscle wasting.<ref>{{Cite journal|last=Evans|first=William J.|last2=Morley|first2=John E.|last3=Argilés|first3=Josep|last4=Bales|first4=Connie|last5=Baracos|first5=Vickie|last6=Guttridge|first6=Denis|last7=Jatoi|first7=Aminah|last8=Kalantar-Zadeh|first8=Kamyar|last9=Lochs|first9=Herbert|date=2008-12-01|title=Cachexia: a new definition|journal=Clinical Nutrition|volume=27|issue=6|pages=793–799|doi=10.1016/j.clnu.2008.06.013|issn=1532-1983|pmid=18718696}}</ref><br />The major objective was to bring together a multi-disciplinary team of experts in order to develop, as a united body, a consensus of statements<ref>{{Cite book|url=https://books.google.com/books?id=9yM0AgAAQBAJ&pg=PA116&lpg=PA116&dq=morley+society+sarcopenia+cachexia&source=bl&ots=TdUpBErMwF&sig=YyVznsFMxwRR7smlsX_VukODUcI&hl=fr&sa=X&ved=0ahUKEwjVpZ6I9eHQAhVF2BoKHSCICVg4FBDoAQhIMAY#v=onepage&q=morley%20society%20sarcopenia%20cachexia&f=false|title=Advances in Food and Nutrition Research|date=2014-01-30|publisher=Academic Press|isbn=9780128003688|language=en}}</ref> based on the following topics:
Since 2006, the SCWD has also organized several consensus meetings to address issues related to the definition of cachexia, sarcopenia<ref>{{Cite journal|last=Morley|first=John E.|last2=Abbatecola|first2=Angela Marie|last3=Argiles|first3=Josep M.|last4=Baracos|first4=Vickie|last5=Bauer|first5=Juergen|last6=Bhasin|first6=Shalender|last7=Cederholm|first7=Tommy|last8=Coats|first8=Andrew J. Stewart|last9=Cummings|first9=Steven R.|date=2011-07-01|title=Sarcopenia with limited mobility: an international consensus|journal=Journal of the American Medical Directors Association|volume=12|issue=6|pages=403–409|doi=10.1016/j.jamda.2011.04.014|issn=1538-9375|pmc=5100674|pmid=21640657}}</ref> as well the regulatory pathways for treatment development in cachexia, sarcopenia and the syndrome of muscle wasting.<ref>{{Cite journal|last=Evans|first=William J.|last2=Morley|first2=John E.|last3=Argilés|first3=Josep|last4=Bales|first4=Connie|last5=Baracos|first5=Vickie|last6=Guttridge|first6=Denis|last7=Jatoi|first7=Aminah|last8=Kalantar-Zadeh|first8=Kamyar|last9=Lochs|first9=Herbert|date=2008-12-01|title=Cachexia: a new definition|journal=Clinical Nutrition|volume=27|issue=6|pages=793–799|doi=10.1016/j.clnu.2008.06.013|issn=1532-1983|pmid=18718696}}</ref><br />The major objective was to bring together a multi-disciplinary team of experts in order to develop, as a united body, a consensus of statements<ref>{{Cite book|url=https://books.google.com/?id=9yM0AgAAQBAJ&pg=PA116&lpg=PA116&dq=morley+society+sarcopenia+cachexia#v=onepage&q=morley%20society%20sarcopenia%20cachexia&f=false|title=Advances in Food and Nutrition Research|date=2014-01-30|publisher=Academic Press|isbn=9780128003688|language=en}}</ref> based on the following topics:
* Definitions of Cachexia, Sarcopenia<ref>{{Cite journal|last=morley|first=john|year=2011|title=Sarcopenia With Limited Mobility: An International Consensus|url=http://www.jamda.com/article/S1525-8610(11)00142-3/fulltext|journal=jamda|volume=|pages=|via=}}</ref> and Frailty with a proposal for an overall disease classification system of "Muscle Wasting Syndromes" as frame-work of reference.
* Definitions of Cachexia, Sarcopenia<ref>{{Cite journal|last=morley|first=john|year=2011|title=Sarcopenia With Limited Mobility: An International Consensus|url=http://www.jamda.com/article/S1525-8610(11)00142-3/fulltext|journal=Jamda|volume=|pages=|via=}}</ref> and Frailty with a proposal for an overall disease classification system of "Muscle Wasting Syndromes" as frame-work of reference.
* Classification.<ref>{{Cite journal|last=Argilés|first=Josep M.|last2=López-Soriano|first2=Francisco J.|last3=Toledo|first3=Míriam|last4=Betancourt|first4=Angelica|last5=Serpe|first5=Roberto|last6=Busquets|first6=Sílvia|date=2016-12-08|title=The cachexia score (CASCO): a new tool for staging cachectic cancer patients|journal=Journal of Cachexia, Sarcopenia and Muscle|volume=2|issue=2|pages=87–93|doi=10.1007/s13539-011-0027-5|issn=2190-5991|pmc=3117995|pmid=21766054}}</ref>
* Classification.<ref>{{Cite journal|last=Argilés|first=Josep M.|last2=López-Soriano|first2=Francisco J.|last3=Toledo|first3=Míriam|last4=Betancourt|first4=Angelica|last5=Serpe|first5=Roberto|last6=Busquets|first6=Sílvia|date=2016-12-08|title=The cachexia score (CASCO): a new tool for staging cachectic cancer patients|journal=Journal of Cachexia, Sarcopenia and Muscle|volume=2|issue=2|pages=87–93|doi=10.1007/s13539-011-0027-5|issn=2190-5991|pmc=3117995|pmid=21766054}}</ref>
* Body composition assessment.
* Body composition assessment.
Line 64: Line 64:
* What constitutes clinically meaningful change.
* What constitutes clinically meaningful change.
* New regulatory pathways.
* New regulatory pathways.
These consensus gathered together about 30 international scientists, including representatives from regulatory authorities. The invited experts are well recognized academic leaders in geriatrics, oncology, cardiology, pulmonology and regulatory issues. <br />These consensus projects aimed to facilitate the future design and performance of clinical trials in the fields of cachexia and sarcopenia<ref>[https://www.youtube.com/watch?v=GgpLV5ne_HQ&list=PLWpB_WBVrGgr4XCF-mwshQQnN1wcgLx4R/ Definition of Sarcopenia]</ref> They also generated recommendations for nutritional management.<ref>{{Cite book|url=https://books.google.com/books?id=i4AQMl6eASkC&pg=PA110&lpg=PA110&dq=morley+society+sarcopenia+cachexia&source=bl&ots=j1EfXrJHzD&sig=zg0Hj2hINgQN1cZ-_gVgweGKSTM&hl=fr&sa=X&ved=0ahUKEwjtu5iS9OHQAhVFcBoKHWFXDVoQ6AEIYjAJ#v=onepage&q=morley%20society%20sarcopenia%20cachexia&f=false|title=Bioactive Food as Dietary Interventions for the Aging Population|last=Watson|first=Ronald Ross|last2=Preedy|first2=Victor R.|date=2013-01-01|publisher=Academic Press|isbn=9780123971555|language=en}}</ref>
These consensus gathered together about 30 international scientists, including representatives from regulatory authorities. The invited experts are well recognized academic leaders in geriatrics, oncology, cardiology, pulmonology and regulatory issues. <br />These consensus projects aimed to facilitate the future design and performance of clinical trials in the fields of cachexia and sarcopenia<ref>[https://www.youtube.com/watch?v=GgpLV5ne_HQ&list=PLWpB_WBVrGgr4XCF-mwshQQnN1wcgLx4R/ Definition of Sarcopenia]</ref> They also generated recommendations for nutritional management.<ref>{{Cite book|url=https://books.google.com/?id=i4AQMl6eASkC&pg=PA110&lpg=PA110&dq=morley+society+sarcopenia+cachexia#v=onepage&q=morley%20society%20sarcopenia%20cachexia&f=false|title=Bioactive Food as Dietary Interventions for the Aging Population|last=Watson|first=Ronald Ross|last2=Preedy|first2=Victor R.|date=2013-01-01|publisher=Academic Press|isbn=9780123971555|language=en}}</ref>


== Journal ==
== Journal ==
The [[Journal of Cachexia, Sarcopenia and Muscle]] (JCSM) published by [[Wiley-Blackwell]] is the official journal of SCWD.<ref>[http://onlinelibrary.wiley.com/journal/10.1007/13539.2190-6009/ Wiley-Blackwell online library]</ref> According to the ''[[Journal Citation Reports]]'', the journal has a 2016 [[impact factor]] of 9.697. JCSM has seen an increase in citations and submissions in 2016.<ref>[http://www.jcsm.info Journal of Cachexia, Sarcopenia and muscle]</ref> It is ranked in the first 10 journals for all journals in the field of "medicine, general and internal.<ref>{{Cite journal|last=von Haehling|first=Stephan|last2=Anker|first2=Stefan D.|date=2015-09-01|title=Moving on up: the Journal of Cachexia, Sarcopenia and Muscle|url=http://onlinelibrary.wiley.com/doi/10.1002/jcsm.12064/abstract|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=6|issue=3|pages=193–196|doi=10.1002/jcsm.12064|issn=2190-6009|pmc=4575549|pmid=26401464}}</ref>
The [[Journal of Cachexia, Sarcopenia and Muscle]] (JCSM) published by [[Wiley-Blackwell]] is the official journal of SCWD.<ref>[http://onlinelibrary.wiley.com/journal/10.1007/13539.2190-6009/ Wiley-Blackwell online library]</ref> According to the ''[[Journal Citation Reports]]'', the journal has a 2016 [[impact factor]] of 9.697. JCSM has seen an increase in citations and submissions in 2016.<ref>[http://www.jcsm.info Journal of Cachexia, Sarcopenia and muscle]</ref> It is ranked in the first 10 journals for all journals in the field of "medicine, general and internal.<ref>{{Cite journal|last=von Haehling|first=Stephan|last2=Anker|first2=Stefan D.|date=2015-09-01|title=Moving on up: the Journal of Cachexia, Sarcopenia and Muscle|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=6|issue=3|pages=193–196|doi=10.1002/jcsm.12064|issn=2190-6009|pmc=4575549|pmid=26401464}}</ref>


== About Muscle Wasting, Cachexia and Sarcopenia ==
== About Muscle Wasting, Cachexia and Sarcopenia ==


Cachexia is a major issue, especially in the elderly.<ref>{{cite book|last1=Mantovani|first1=Giovanni|title=Cachexia and Wasting: A Modern Approach|date=2006|publisher=Springer|location=Milan|isbn=8847004713|url=https://books.google.com/books?id=lQyGxrmQ17AC&pg=PA383&lpg=PA383&dq=cachexia+epidemic&source=bl&ots=4yu_TUYOdb&sig=q8OmPQNlqnkG0TfEy8wxr9Ygy10&hl=fr&sa=X&ved=0ahUKEwju9vej7uHQAhULWRoKHbJGBDUQ6AEINTAF#v=onepage&q=cachexia%20epidemic&f=true}}</ref> Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease,and stroke.<ref>{{Cite journal|last=Anker|first=Stefan D.|last2=Morley|first2=John E|date=2015-12-01|title=Cachexia: a nutritional syndrome?|url=http://onlinelibrary.wiley.com/doi/10.1002/jcsm.12088/abstract|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=6|issue=4|pages=269–271|doi=10.1002/jcsm.12088|issn=2190-6009|pmc=4670732|pmid=26675043}}</ref> Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity / mortality.
Cachexia is a major issue, especially in the elderly.<ref>{{cite book|last1=Mantovani|first1=Giovanni|title=Cachexia and Wasting: A Modern Approach|date=2006|publisher=Springer|location=Milan|isbn=978-8847004719|url=https://books.google.com/?id=lQyGxrmQ17AC&pg=PA383&lpg=PA383&dq=cachexia+epidemic#v=onepage&q=cachexia%20epidemic&f=true}}</ref> Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease,and stroke.<ref>{{Cite journal|last=Anker|first=Stefan D.|last2=Morley|first2=John E|date=2015-12-01|title=Cachexia: a nutritional syndrome?|journal=Journal of Cachexia, Sarcopenia and Muscle|language=en|volume=6|issue=4|pages=269–271|doi=10.1002/jcsm.12088|issn=2190-6009|pmc=4670732|pmid=26675043}}</ref> Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity / mortality.
Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia.<ref>{{Cite journal|last=Evans|first=William J.|date=2010-04-01|title=Skeletal muscle loss: cachexia, sarcopenia, and inactivity|url=http://ajcn.nutrition.org/content/91/4/1123S|journal=The American Journal of Clinical Nutrition|language=en|volume=91|issue=4|pages=1123S–1127S|doi=10.3945/ajcn.2010.28608A|issn=0002-9165|pmid=20164314}}</ref> Sarcopenia and cachexia represent the major causes of muscle-wasting disorders.
Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia.<ref>{{Cite journal|last=Evans|first=William J.|date=2010-04-01|title=Skeletal muscle loss: cachexia, sarcopenia, and inactivity|url=http://ajcn.nutrition.org/content/91/4/1123S|journal=The American Journal of Clinical Nutrition|language=en|volume=91|issue=4|pages=1123S–1127S|doi=10.3945/ajcn.2010.28608A|issn=0002-9165|pmid=20164314}}</ref> Sarcopenia and cachexia represent the major causes of muscle-wasting disorders.
It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.<br /> It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.<ref>{{Cite journal|last=Morley|first=John E.|date=2016-09-26|title=Frailty and sarcopenia in elderly|journal=Wiener Klinische Wochenschrift|doi=10.1007/s00508-016-1087-5|issn=1613-7671|pmid=27670855|volume=128|pages=439–445}}</ref><br />
It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.<br /> It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.<ref>{{Cite journal|last=Morley|first=John E.|date=2016-09-26|title=Frailty and sarcopenia in elderly|journal=Wiener Klinische Wochenschrift|doi=10.1007/s00508-016-1087-5|issn=1613-7671|pmid=27670855|volume=128|issue=Suppl 7|pages=439–445}}</ref><br />
Cachexia and sarcopenia are both characterized by an important muscle dysfunction and weakness<ref>{{Cite news|url=https://www.curetoday.com/articles/patients-suffering-from-cachexia-need-nutritional-support|title=Patients Suffering From Cachexia Need Nutritional Support|work=Cure Today|access-date=2018-02-09}}</ref> that lead to increased morbidity and mortality.<ref>{{Cite journal|last=von Haehling|first=Stephan|last2=Anker|first2=Markus S.|last3=Anker|first3=Stefan D.|date=2016-12-01|title=Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016|journal=Journal of Cachexia, Sarcopenia and Muscle|volume=7|issue=5|pages=507–509|doi=10.1002/jcsm.12167|issn=2190-6009|pmc=5114624|pmid=27891294}}</ref> The cost of muscle wasting is high.<ref>{{Cite web|url=http://www.huffingtonpost.com/brent-green/baby-boomers-sarcopenia_b_1108933.html|title=Follow The Boomer Money: End Of Sarcopenia, Compression Of Morbidity|last=Author|first=Brent Green|last2=Boomers"|first2="Marketing to Leading-Edge Baby|date=2011-12-06|website=The Huffington Post|access-date=2016-12-07|last3=Reinvention|first3="Generation|last4=Speaker|first4="|last5=Host|first5=Radio}}</ref>
Cachexia and sarcopenia are both characterized by an important muscle dysfunction and weakness<ref>{{Cite news|url=https://www.curetoday.com/articles/patients-suffering-from-cachexia-need-nutritional-support|title=Patients Suffering From Cachexia Need Nutritional Support|work=Cure Today|access-date=2018-02-09}}</ref> that lead to increased morbidity and mortality.<ref>{{Cite journal|last=von Haehling|first=Stephan|last2=Anker|first2=Markus S.|last3=Anker|first3=Stefan D.|date=2016-12-01|title=Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016|journal=Journal of Cachexia, Sarcopenia and Muscle|volume=7|issue=5|pages=507–509|doi=10.1002/jcsm.12167|issn=2190-6009|pmc=5114624|pmid=27891294}}</ref> The cost of muscle wasting is high.<ref>{{Cite web|url=http://www.huffingtonpost.com/brent-green/baby-boomers-sarcopenia_b_1108933.html|title=Follow The Boomer Money: End Of Sarcopenia, Compression Of Morbidity|last=Author|first=Brent Green|last2=Boomers"|first2="Marketing to Leading-Edge Baby|date=2011-12-06|website=The Huffington Post|access-date=2016-12-07|last3=Reinvention|first3="Generation|last4=Speaker|first4="|last5=Host|first5=Radio}}</ref>


Revision as of 05:19, 30 August 2018

The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is an international and multidisciplinary non-profit organization.[1] It focuses on Cachexia[2] and Sarcopenia.

Cachexia and sarcopenia are a major public health problem: frequent, costly, and deadly.[3] . They are often under-diagnosed and patients groups try to improve awareness about them[4]. Cachexia has been coined as the "last illness".[5] The prevalence of cachexia ranges from 5–15% in end-stage chronic heart failure to 50–80% in advanced malignant cancer.[6] It is estimated that 5 Million Americans have the condition and Cachexia is frequently occurring in patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD), HIV, Multiple sclerosis, neurological diseases, and rheumatoid arthritis.[7] Mortality rates of patients with cachexia range from 15–25% per year in severe COPD through 20–40% per year in patients with chronic heart failure or chronic kidney disease to 20–80% in cancer cachexia.[8] SCWD was founded in 2008 on the initiative of Prof. Stefan D. Anker,[9] Germany and Dr. John E. Morley,[10] USA. It is made up of an international and multidisciplinary group of healthcare professionals in the fields of sarcopenia, cachexia and muscle wasting.[11]

The purpose and objectives of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) are to:

  • To improve the understanding, diagnosis and treatment of skeletal muscle wasting in various disease conditions and aging[12]
  • Educate healthcare professionals
  • Form partnerships with other professional societies[13]

Legal Structure and Board

The Society on Sarcopenia, Cachexia and Wasting Disorders is a non-profit scientific organization (501 c3)[14] registered in the United States of America and Switzerland. The president is Prof. Stefan Anker, Germany who is also vice-president of the European Society of Cardiology,[15] the Vice-president is Dr. John Morley, USA and the treasurer is Prof. Andrew J. Coats, United Kingdom who particularly investigated cardiac cachexia at an early stage.[16]
The Board is made up of :
Stefan D. Anker (President[17]) – Berlin, Germany
Josep M. Argiles – Barcelona, Spain
Vickie E. Baracos – Edmonton, Canada
Andrew J. S. Coats (Treasurer) – Norwich, UK
Wolfram Doehner – Berlin, Germany
William J. Evans[18] – Duke University, USA
Luigi Ferrucci[19] – Baltimore, USA
David J. Glass – Boston, USA
Akio Inui – Kobe, Japan
Aminah Jatoi – Rochester, USA
Kamyar Kalantar-Zadeh – Los Angeles, USA
John E. Morley (Vice-president) – St. Louis, USA
Filippo Rossi-Fanelli – Rome, Italy
Florian Strasser – St. Gallen, Switzerland
Stephan von Haehling – Göttingen, Germany

Prof Ken Fearon was a Board member until he passed away in September 2016.[20] He had received the Hippocrates Award from the Society.[21] Professor Fearon was particularly involved in cancer cachexia: leading an international consensus.[22]

Educational initiatives

Conferences

Since 2000[23] the SCWD Society has organized several international conferences.[24] In 2009, the conference[25] took place in Barcelona, Spain. In 2011, the 7th conference took place in Italy.[26] One of them took place in Kobe,[27] Japan. Those conferences have taken place every two years. However, in 2015, in Paris,[28] it was decided to organize the conferences annually.[29] The location of the 2016 congress is Berlin on 10–11 December 2016.[30] The programme includes a statistical seminar, a mentor or career session and sessions on cachexia, sarcopenia and muscle wasting.[31]

It addresses frailty, sarcopenia and cachexia resulting from the following diseases or chronic conditions: Cancer, Cardiovascular Disease, Death, Dying & Grief, Dementia/Alzheimer's Disease, Diabetes, Heart Failure and Ageing.[32] Update on Anabolics and Related Therapie sare also provided.[33] Results of clinical trials are also presented, such a sdata from a Phase II clinical trial of MT-102 in cancer-related cachexia presented in Kobe in 2013.[34]


Target audience: Internists, Oncologists, Geriatricians, Cardiologists, Nephrologists, Palliative care specialists, Nurse Practitioners and Primary Care Providers.

Attendance:[35]

Year Congress Venue No of Registered Delegates
2000 1st Berlin 150
2003 2nd Berlin 250
2005 3rd Rome 300
2007 4th Tampa 340
2009 5th Barcelona 410
2011 6th Milano 450
2013 7th Kobe 390
2015 8th Paris 500


A charity dinner is sometimes organised during SCWD Conférences such as in 2011 in Milan with the participation of Lisa Niemi.[36]

Posters: each meeting features 120-200 posters.[37]

The SCWD releases regular highlights of its meetings.[38]

Consensus meetings

Since 2006, the SCWD has also organized several consensus meetings to address issues related to the definition of cachexia, sarcopenia[39] as well the regulatory pathways for treatment development in cachexia, sarcopenia and the syndrome of muscle wasting.[40]
The major objective was to bring together a multi-disciplinary team of experts in order to develop, as a united body, a consensus of statements[41] based on the following topics:

  • Definitions of Cachexia, Sarcopenia[42] and Frailty with a proposal for an overall disease classification system of "Muscle Wasting Syndromes" as frame-work of reference.
  • Classification.[43]
  • Body composition assessment.
  • End-points in clinical trials including Patient-reported outcomes.
  • Nutrition.[44]
  • Endpoint in clinical trials: strengths and weaknesses.
  • What constitutes clinically meaningful change.
  • New regulatory pathways.

These consensus gathered together about 30 international scientists, including representatives from regulatory authorities. The invited experts are well recognized academic leaders in geriatrics, oncology, cardiology, pulmonology and regulatory issues.
These consensus projects aimed to facilitate the future design and performance of clinical trials in the fields of cachexia and sarcopenia[45] They also generated recommendations for nutritional management.[46]

Journal

The Journal of Cachexia, Sarcopenia and Muscle (JCSM) published by Wiley-Blackwell is the official journal of SCWD.[47] According to the Journal Citation Reports, the journal has a 2016 impact factor of 9.697. JCSM has seen an increase in citations and submissions in 2016.[48] It is ranked in the first 10 journals for all journals in the field of "medicine, general and internal.[49]

About Muscle Wasting, Cachexia and Sarcopenia

Cachexia is a major issue, especially in the elderly.[50] Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease,and stroke.[51] Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity / mortality. Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia.[52] Sarcopenia and cachexia represent the major causes of muscle-wasting disorders. It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.
It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.[53]
Cachexia and sarcopenia are both characterized by an important muscle dysfunction and weakness[54] that lead to increased morbidity and mortality.[55] The cost of muscle wasting is high.[56]

References

  1. ^ "Come Together to support a cause that matters to you!". Retrieved 2016-12-07.
  2. ^ What is cancer cachexia
  3. ^ Farkas, Jerneja; von Haehling, Stephan; Kalantar-Zadeh, Kamyar; Morley, John E.; Anker, Stefan D.; Lainscak, Mitja (2016-12-07). "Cachexia as a major public health problem: frequent, costly, and deadly". Journal of Cachexia, Sarcopenia and Muscle. 4 (3): 173–178. doi:10.1007/s13539-013-0105-y. ISSN 2190-5991. PMC 3774921. PMID 23539127.
  4. ^ McDaniels, Andrea K. "Groups seek better diagnosis and treatment of debilitating muscle loss in seniors". baltimoresun.com. Retrieved 2018-02-09.
  5. ^ Lok, Corie (2015-12-10). "Cachexia: The last illness". Nature. 528 (7581): 182–183. doi:10.1038/528182a. PMID 26659165.
  6. ^ [1]
  7. ^ "Cachexia: Symptoms, Treatment, and Outlook". Medical News Today. Retrieved 2017-01-24.
  8. ^ von Haehling, Stephan; Anker, Markus S.; Anker, Stefan D. (2016-12-01). "Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016". Journal of Cachexia, Sarcopenia and Muscle. 7 (5): 507–509. doi:10.1002/jcsm.12167. ISSN 2190-6009. PMC 5114624. PMID 27891294.
  9. ^ "Curriculum vitae" (PDF).
  10. ^ "One of the nation' foremost authorities on geriatrics". Saint Louis University.
  11. ^ "The Society On Sarcopenia, Cachexia & Wasting Disorders Announces Its 1st Cancer Cachexia Conference In Boston, USA". Newswire.
  12. ^ "Society on sarcopenia, cachexia and wasting disorders". research.longfonds.nl. Retrieved 2016-12-07.
  13. ^ "Journal of Cachexia, Sarcopenia and Muscle - Society Information -". Wiley Online Library. doi:10.1007/13539.2190-6009/homepage/Society (inactive 2018-08-30). {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: DOI inactive as of August 2018 (link)
  14. ^ [2]
  15. ^ "ESC Board". www.escardio.org. Retrieved 2016-12-07.
  16. ^ Coats, Andrew JS (2002). "Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath". International Journal of Cardiology. 85: 133–139. doi:10.1016/s0167-5273(02)00242-5.
  17. ^ "This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know". Prevention. 2017-09-27. Retrieved 2018-02-09.
  18. ^ [3]
  19. ^ [4]
  20. ^ "editorial". Clinical Nutrition.
  21. ^ "Obituary - Kenneth Fearon, professor of surgical oncology". HeraldScotland. Retrieved 2016-12-07.
  22. ^ Fearon, Kenneth; Strasser, Florian; Anker, Stefan D.; Bosaeus, Ingvar; Bruera, Eduardo; Fainsinger, Robin L.; Jatoi, Aminah; Loprinzi, Charles; MacDonald, Neil (2011-05-01). "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology. 12 (5): 489–495. doi:10.1016/S1470-2045(10)70218-7. ISSN 1474-5488. PMID 21296615.
  23. ^ Anker, Markus S.; von Haehling, Stephan; Springer, Jochen; Banach, Maciej; Anker, Stefan D. (2013-02-21). "Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology". Archives of Medical Science : AMS. 9 (1): 166–171. doi:10.5114/aoms.2013.33356. ISSN 1734-1922. PMC 3598129. PMID 23515589.
  24. ^ "Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5–8, 2009". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 43–128. 2010-09-01. doi:10.1007/s13539-010-0001-7. ISSN 2190-6009. PMC 3060650. PMID 22477519.
  25. ^ http://medschool.slu.edu/uploads/images/5th_Cachexia_Conference_2009.pdf. {{cite web}}: Missing or empty |title= (help)
  26. ^ http://www.huffingtonpost.com/andrew-dudley/elderly-women-prefer-deat_b_5114875.html. {{cite web}}: Missing or empty |title= (help)
  27. ^ http://www.cancercachexia.com/literature-watch/84_congress-report-7th-cachexia-conference-kobeosaka-japan-december. {{cite web}}: Missing or empty |title= (help)
  28. ^ [5]
  29. ^ von Haehling, S; Anker, SD (2016-02-22). "The times they are a‐changin': the Cachexia Conference goes annual". Journal of Cachexia, Sarcopenia and Muscle. 7 (1): 3–4. doi:10.1002/jcsm.12110. PMC 4771211. PMID 27066313.
  30. ^ cancercachexia2016 http://cancercachexia2016.com/html/events.html. {{cite web}}: Missing or empty |title= (help)
  31. ^ http://www.sinu.it/public//program-berlin-7-10.pdf. {{cite web}}: Missing or empty |title= (help)
  32. ^ von Haehling, Stephan; Anker, Stefan D. (2010-09-01). "Cachexia as a major underestimated and unmet medical need: facts and numbers". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 1–5. doi:10.1007/s13539-010-0002-6. ISSN 2190-6009. PMC 3060651. PMID 21475699.
  33. ^ Group, Helsinn. "Helsinn Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung /PR Newswire UK/". www.prnewswire.co.uk. Retrieved 2016-12-08.
  34. ^ "Lundbeckfond Ventures ' MID-STAGE CLINICAL STUDY OF WASTING DISEASE THERAPEUTIC MT-102 SHOWS REVERSAL OF CANCER-RELATED WASTING". www.lundbeckfonden.com. Retrieved 2016-12-12.
  35. ^ Haehling, Stephan von; Anker, Stefan D. (2011-11-09). "The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area". Journal of Cachexia, Sarcopenia and Muscle. 2 (4): 189–190. doi:10.1007/s13539-011-0048-0. ISSN 2190-5991. PMC 3222803. PMID 22207906.
  36. ^ "6th Cachexia Conference: Lisa Niemi-Swayze Slated as Keynote Speaker at SCWD Charity Dinner". www.newswire.com. Retrieved 2016-12-07.
  37. ^ "Abstracts of the 6th Cachexia Conference, Milan, Italy, December 8–10, 2011 (Part 2)". Journal of Cachexia, Sarcopenia and Muscle. 3 (1): 51–68. 2012-01-31. doi:10.1007/s13539-012-0056-8. ISSN 2190-5991. PMC 3302985. PMID 22460563.
  38. ^ Ebner, Nicole; Werner, Claudia G.; Doehner, Wolfram; Anker, Stefan D.; Haehling, Stephan von (2012-03-02). "Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference". Journal of Cachexia, Sarcopenia and Muscle. 3 (1): 45–50. doi:10.1007/s13539-012-0061-y. ISSN 2190-5991. PMC 3302986. PMID 22460618.
  39. ^ Morley, John E.; Abbatecola, Angela Marie; Argiles, Josep M.; Baracos, Vickie; Bauer, Juergen; Bhasin, Shalender; Cederholm, Tommy; Coats, Andrew J. Stewart; Cummings, Steven R. (2011-07-01). "Sarcopenia with limited mobility: an international consensus". Journal of the American Medical Directors Association. 12 (6): 403–409. doi:10.1016/j.jamda.2011.04.014. ISSN 1538-9375. PMC 5100674. PMID 21640657.
  40. ^ Evans, William J.; Morley, John E.; Argilés, Josep; Bales, Connie; Baracos, Vickie; Guttridge, Denis; Jatoi, Aminah; Kalantar-Zadeh, Kamyar; Lochs, Herbert (2008-12-01). "Cachexia: a new definition". Clinical Nutrition. 27 (6): 793–799. doi:10.1016/j.clnu.2008.06.013. ISSN 1532-1983. PMID 18718696.
  41. ^ Advances in Food and Nutrition Research. Academic Press. 2014-01-30. ISBN 9780128003688.
  42. ^ morley, john (2011). "Sarcopenia With Limited Mobility: An International Consensus". Jamda.
  43. ^ Argilés, Josep M.; López-Soriano, Francisco J.; Toledo, Míriam; Betancourt, Angelica; Serpe, Roberto; Busquets, Sílvia (2016-12-08). "The cachexia score (CASCO): a new tool for staging cachectic cancer patients". Journal of Cachexia, Sarcopenia and Muscle. 2 (2): 87–93. doi:10.1007/s13539-011-0027-5. ISSN 2190-5991. PMC 3117995. PMID 21766054.
  44. ^ Morley, John E.; Argiles, Josep M.; Evans, William J.; Bhasin, Shalender; Cella, David; Deutz, Nicolaas E. P.; Doehner, Wolfram; Fearon, Ken C. H.; Ferrucci, Luigi (2010-07-01). "Nutritional recommendations for the management of sarcopenia". Journal of the American Medical Directors Association. 11 (6): 391–396. doi:10.1016/j.jamda.2010.04.014. ISSN 1538-9375. PMC 4623318. PMID 20627179.
  45. ^ Definition of Sarcopenia
  46. ^ Watson, Ronald Ross; Preedy, Victor R. (2013-01-01). Bioactive Food as Dietary Interventions for the Aging Population. Academic Press. ISBN 9780123971555.
  47. ^ Wiley-Blackwell online library
  48. ^ Journal of Cachexia, Sarcopenia and muscle
  49. ^ von Haehling, Stephan; Anker, Stefan D. (2015-09-01). "Moving on up: the Journal of Cachexia, Sarcopenia and Muscle". Journal of Cachexia, Sarcopenia and Muscle. 6 (3): 193–196. doi:10.1002/jcsm.12064. ISSN 2190-6009. PMC 4575549. PMID 26401464.
  50. ^ Mantovani, Giovanni (2006). Cachexia and Wasting: A Modern Approach. Milan: Springer. ISBN 978-8847004719.
  51. ^ Anker, Stefan D.; Morley, John E (2015-12-01). "Cachexia: a nutritional syndrome?". Journal of Cachexia, Sarcopenia and Muscle. 6 (4): 269–271. doi:10.1002/jcsm.12088. ISSN 2190-6009. PMC 4670732. PMID 26675043.
  52. ^ Evans, William J. (2010-04-01). "Skeletal muscle loss: cachexia, sarcopenia, and inactivity". The American Journal of Clinical Nutrition. 91 (4): 1123S–1127S. doi:10.3945/ajcn.2010.28608A. ISSN 0002-9165. PMID 20164314.
  53. ^ Morley, John E. (2016-09-26). "Frailty and sarcopenia in elderly". Wiener Klinische Wochenschrift. 128 (Suppl 7): 439–445. doi:10.1007/s00508-016-1087-5. ISSN 1613-7671. PMID 27670855.
  54. ^ "Patients Suffering From Cachexia Need Nutritional Support". Cure Today. Retrieved 2018-02-09.
  55. ^ von Haehling, Stephan; Anker, Markus S.; Anker, Stefan D. (2016-12-01). "Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016". Journal of Cachexia, Sarcopenia and Muscle. 7 (5): 507–509. doi:10.1002/jcsm.12167. ISSN 2190-6009. PMC 5114624. PMID 27891294.
  56. ^ Author, Brent Green; Boomers", "Marketing to Leading-Edge Baby; Reinvention, "Generation; Speaker, "; Host, Radio (2011-12-06). "Follow The Boomer Money: End Of Sarcopenia, Compression Of Morbidity". The Huffington Post. Retrieved 2016-12-07. {{cite web}}: |first4= has numeric name (help); |last= has generic name (help)

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Society_on_Sarcopenia,_Cachexia_and_Wasting_Disorders&oldid=857197208"